Fig. 5: Myeloid cell immunomodulation by C′ dots. | Nature Nanotechnology

Fig. 5: Myeloid cell immunomodulation by C′ dots.

From: An ultrasmall core–shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironments

Fig. 5: Myeloid cell immunomodulation by C′ dots.

a, Schematic of experimental procedure to isolate/culture BMDMs and splenocytes (T cells) from B16-GM tumour-bearing mice for treatment. b, Differential fold changes of select genes in BMDMs exposed to either particle (15 μM) or saline vehicle for 48 h and assayed using RT-qPCR; largest differentials are boxed. c, Cytokine secretion analysis of supernatants from b. d, Flow cytometric analysis of CD11b+ cells 48 h post-treatment. e, Percentage (%) of tumour cells phagocytosed by co-cultured BMDMs using flow cytometry 48 h after exposing the former to particles or vehicle. f,g, Analysis of type I IFN (f) and cGAMP (g) production via B16-Blue cells and ELISA, respectively. Data represent mean ± s.e.m. for particle-treated and control groups (n = 3 mice per group) reflecting 2 independent experiments. Unpaired Student’s t-test and non-parametric one-way ANOVA with Tukey’s test for multiple comparisons were performed. All statistical tests were two-sided. *P < 0.05, **P < 0.01, ***P < 0.005 and ****P < 0.001. Schematics in a created with BioRender.com.

Back to article page